The average Discovery Award is £3.5 million, with applications over £5 million receiving extra scrutiny. - September 22, 2026
Wellcome Trust
This scheme provides funding for established researchers and teams from any discipline who want to pursue bold and creative research ideas to deliver significant shifts in understanding related to human life, health and wellbeing.
Total of up to $1,350,000 annually - September 15, 2026
ResMed Foundation
The ResMed Foundation supports innovative research and awareness of sleep-disordered breathing and other respiratory disorders, focusing on diagnosis, treatment.
Up to $5,000,000 based on stage and scope of research. - Monday,September 14, 2026 (LOI)
Alzheimer's Drug Discovery Foundation
This RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and earlyphase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias.
Up to $5,000,000 for clinical trials based on stage and scope of research. - Monday, September 14, 2026 (LOI)
Alzheimer's Drug Discovery Foundation
This initiative supports research on precision prevention, combination therapies, and comparative effectiveness to reduce Alzheimer’s and dementia risk.
Up to $600,000 based on stage and scope of research.Only direct costs are allowed. - Monday, September 14, 2026 (LOI)
Alzheimer's Drug Discovery Foundation
The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias.
Maximum of $200,000 direct costs for 2 years - June 17, 2026 (LOI); September 9, 2026 (full proposal)
National Multiple Sclerosis Society
This request for applications (RFA) aims to support early, developmental, and feasibility studies that will address critical gaps in understanding how chronological and biological aging affect MS.
Pfeizer supports Investigator Suponsored Research (ISR) projects that advance medical and scientific knowledge about their therapies. the global program is open to all researchers who are interested in conducting their own research.
$75,000 per year and $150,000 total, inclusive of both direct and indirect costs for the two-year project. - May 18, 2026 (LOI); September 8, 2026 (Invited Full Proposal)
Tuberous Sclerosis Alliance
This program supports innovative research on tuberous sclerosis complex (TSC) and epilepsy, focusing on phenotypic variability, signaling pathways, disease models, biomarkers, and new technologies, while addressing key needs.
Clinical Trial Grant: $200,000 | 3 years; Young Investigator Grant: $100,000 | 3 years - June 1, 2026 (LOI); September 1, 2026 (application)
Cannonball Kids’ cancer (CKc) Foundation
The Foundation prioritizes funding clinical trials, near- clinical research, and young researchers, with a focus on underfunded cancers and underserved patient population.
Up to €500,000 per year, for a maximum duration of three years, depending on the focus area. - Monday, August 31, 2026
MERCK GROUP
Merck's 2026 funding call invites proposals across five priority areas neuroinflammatory disease models, AI in cell culture, remediation technologies, cell-free screening assays, and molecule synthesis.
Wellcome Trust
ResMed Foundation
Alzheimer's Drug Discovery Foundation
National Multiple Sclerosis Society
Tuberous Sclerosis Alliance
Cannonball Kids’ cancer (CKc) Foundation
Pure Earth
CURE (Citizens United for Research in Epilepsy)
MERCK GROUP
